ATAD3A and neoplasm: Multiple studies have revealed that ATAD3A acts as an anti‐apoptotic regulator and is involved in chemo‐resistance during tumor treatment, suggesting it is an attractive target in combination with chemotherapy.[49, 50, 51] We show that a blocking peptide TAT‐PEP targeting ATAD3A phosphorylation prevented doxorubicin‐induced senescence and promoted tumor cell apoptosis, thereby sensitizing the tumor cells to chemotherapy.